Table 2.

Factors associated with stable long-term virological response^* in 609 patients included in the APROCO-COPILOTE cohort assessed for CCR5 Δ32 deletion

Variables	Month 4 to year 3							Month 4 to year 5
	Univariable analysis				Multivariable analysis			Univariable analysis				Multivariable analysis
	%success	OR	95% CI	p	OR	95% CI	p	%success	OR	95% CI	p	OR	95% CI	p
CCR5 deletion				0.02			0.09				0.01			0.04
Δ32/wt	65	1.74	1.10–2.75		1.59	0.93–2.73		48	1.77	1.12–2.78		1.77	1.03–3.04
wt/wt	52	1			1			35	1			1
Sex				0.44			0.89				0.67			0.22
Male	55	1			1			37	1			1
Female	51	0.85	0.57–1.28		1.04	0.61–1.76		35	0.91	0.59–1.40		1.42	0.81–2.48
Age (years)				0.23			0.91				0.003			0.33
<37	52	1			1			31	1			1
≥37	57	1.22	0.88–1.68		0.98	0.67–1.44		43	1.69	1.19–2.38		1.22	0.82–1.83
Origin of birth				0.07			0.14				0.13			0.12
Africa	45	0.63	0.38–1.04		0.65	0.36–1.16		29	0.64	0.36–1.14		0.61	0.32–1.14
Other	57	1			1			39	1			1
Contamination group				0.58			0.69				0.15			0.27
Homo/bisexual	56	1.10	0.79–1.52		0.92	0.60–1.41		40	1.29	0.91–1.82		1.29	0.82–2.01
Other	54	1			1			34	1			1
HIV-RNA at baseline(log₁₀ copies/ml)				0.17			0.09				0.32			0.56
<3,7	62	1			1			38	1			1
[3,7 ;4,5[	49	0.60	0.38–0.94		0.57	0.34–0.98		31	0.72	0.44–1.17		0.68	0.39–1.20
[4,5 ; 5,2[	55	0.77	0.49–1.21		0.60	0.33–1.07		39	1.02	0.64–1.63		0.84	0.45–1.56
≥5,2	53	0.71	0.44–1.13		0.45	0.23–0.87		41	1.12	0.69–1.81		0.71	0.35–1.41
CD4/mm ³ at baseline				0.002			0.004				0.04			0.06
<200	52	0.46	0.27–0.78		0.36	0.19–0.69		39	0.77	0.45–1.29		0.52	0.27–1.00
[350–500[	46	0.36	0.20–0.62		0.33	0.17–0.62		28	0.46	0.26–0.81		0.40	0.21–0.79
[200–350[	59	0.61	0.34–1.10		0.51	0.26–1.01		38	0.72	0.41–1.27		0.54	0.27–1.06
≥500	71	1			1			46	1			1
Time spent on cART^**(months)				<0.0001			<0.0001					-		-
>35	62	3.70	2.47–5.52		3.57	2.24–5.69		-	-		-		-
≤35	31	1			1
Time spent on cART^**(months)					-	-					<0.0001			<0.0001
>55	-	-	-	-			-	44	5.91	3.34–10.46		6.15	3.28–11.53
≤55								12	1			1
Adherence				0.001			0.02				0.0011			0.02
non adherence	30	0.27	0.12–0.62		0.25	0.09–0.68		14	0.20	0.06–0.61		0.28	0.08–0.94
low adherence	42	0.44	0.26–0.75		0.54	0.30–0.99		24	0.39	0.22–0.71		0.41	0.21–0.80
moderate adherence	56	0.78	0.54–1.13		0.84	0.55–1.30		36	0.70	0.48–1.02		0.68	0.44–1.04
high adherence	67	1			1			50	1			1
Prior antiretroviral treatment				0.0003			<0.0001				0.0001			0.002
yes	63	1.84	1.32–2.55		2.98	1.85–4.79		46	1.95	1.38–2.75		2.18	1.33–3.55
no	48	1			1			30	1			1

stable virological response defined as plasma HIV-1 RNA measurement below the threshold of detection of 500 copies/ml at all measurements except once between M4 and year 3 and 5.

^**

cART: combination antiretroviral treatment